Drug Plan Trends Report: A snapshot of what’s coming down the pike
Posted by Medavie Blue Cross on March 20, 2018
Medavie Blue Cross has also seen a significant decline in new patient starts for hepatitis C medications, says Chris Goguen, the insurer’s strategic pharmaceutical partnerships lead in Moncton, N.B. Demand is now one-fifth of the volume it was a year-and-a-half ago, although there may be a slight bump if and when the medications are approved for more indications, says Christine Than, a pharmacist and drug solutions specialist at Aon Hewitt in Montreal.
For over 75 years, Medavie Blue Cross has been a leading health services partner for individuals, employers and governments across Canada. As the country’s leading Blue Cross plan with over one million card holders, we are a premier all-in-one carrier that provides health, dental, travel, life and disability benefits to...
